1. CDHT ranks 6th in the competitiveness list of China’s biomedicine parks

A few days ago, the grand event in biology community —

the First China Biotech Innovation Conference was staged in CDHT.

With the theme of “Drawing Blueprints, Creating a Bright Future”,

this conference invited academicians, experts and scholars, as well as multinational pharmaceutical enterprises,

and famous pharmaceutical enterprises at home and abroad to gather in Chengdu

and discuss China’s biotech innovation development.

At the Closing Ceremony on the afternoon of November 4, the blockbusting report and ranking list, the Report on the Analysis of Current Situation of the Development of China’s Biomedicine Industrial Parks in 2019 was released. The competitiveness ranking of China’s biomedicine parks in 2019 was also published and the top ten parks were awarded.

 

Biomedicine industrial parks have been built along with high-tech zones.

Since the 1990s,

China has built a large number of outstanding industrial parks.

How are these parks developing?

Which models are worth learning from?

The Report on the Analysis of Current Situation of the Development of China’s Biomedicine Industrial Parks in 2019

will give you answers.

The report comprehensively and systematically

compares the data of the parks surveyed in recent 3 years,

with a total of 198 items of 34 themes,

including the status quo of the industry and the transfer of achievements,

R&D input, technical output, talent, enterprises, products and environment.

 

 

Primary index system

Five indexes, i.e. environmental competitiveness, industrial competitiveness, technological competitiveness, talent competitiveness and leading competitiveness

 

 

Secondary index system

24 items, including the output value and growth rate of biomedicine, biological R&D investment and R&D personnel

 

A total of 107 national high-tech zones, 78 national economic development zones and 4 other parks (189 parks in total) participated in the competition.

 

Environmental competitiveness consists of development policy environment, supporting system, urban livability, etc.

 

The biomedicine industry values technology very much, while technological progress can boost the industrial development. Therefore, technological competitiveness is also deemed as an important index, including thesis paper, patent and national projects applied.

 

The industrial scale and quality are also regarded as assessment standards, known as industrial competitiveness.

 

The competitiveness ranking of China’s biomedicine parks in 2019 consists of the ranking of individual competitiveness and the ranking of comprehensive competitiveness. The individual competitiveness includes environmental competitiveness, industrial competitiveness, technological competitiveness, talent competitiveness and leading competitiveness.

 

 

 

Among the high-profile ranking of comprehensive competitiveness, the top 10 are:

 

Zhongguancun Science Park

Shanghai Zhangjiang Hi-Tech Industrial Development Zone

Suzhou Industrial Park

Wuhan East Lake High-tech Development Zone

Jinan Innovation Zone

Chengdu Hi-tech Industrial Development Zone

Shenzhen Hi-tech Industrial Development Zone

Shijiazhuang Hi-tech Industrial Development Zone

Guangzhou Hi-tech Industrial Development Zone

Tianjin Binhai High-tech Industrial Development Zone

On the ranking list of comprehensive competitiveness

of China’s biomedicine parks in 2019,

CDHT ranked 6th.

By virtue of its unique advantages and positioning,

CDHT attracted wide attention from the guests.

In recent years, the biotechnology industry of Chengdu has undergone rapid development. This is not only benefited from natural resources of the Land of Abundance, but also closely related to the planning and investment of the local government and enterprises. Chengdu is rich in biomedical resources, making it further develop in this aspect. Besides, Chengdu has unique conditions and positioning. It can find its own unique direction in culture, society, innovation and other fields in China and even the world.

—Academician Zhang Xu from the Chinese Academy of Sciences

 

CDHT is competitive in the ranking lists of comprehensive competition and some individual competition. It has planned a large area of the biological industry and a large number of achievements have been transferred relying on Sichuan University and West China Hospital. Besides, it ranks high in the number and area of incubator and re-incubation achievements.

— Relevant responsible person of China National Center for Biotechnology Development

 

It is the first time that the conference was held in CDHT.

Here, many other industry conferences have been held.

These industry conferences

are strong boosters for rapid and high-quality development of

the biomedical industry of CDHT.

 

 

 

From January to September this year, enterprises above the designated size in the biological industry in CDHT realized an output value of RMB 18.43 billion, and the revenue of the main business of the medical industry above the designated size was RMB 17.67 billion, an increase of 20.5%.

 

● There were 742 newly registered enterprises in the health industry, a year-on-year increase of 27.4%.

 

● There were 11 new varieties worth RMB 100 million. Chengdu Brilliant Pharmaceutical Group has been listed on the Top 100 Companies in Medical Industry in China for several years, 8 places up compared to the previous year. HitGen’s application for listing on science and technology innovation board was accepted.

 

● There were 70 new Class I drugs and 27 varieties of new Class I drugs under clinical experiment. The new drug for prostatic cancer of Hinova Pharmaceuticals Inc. has been subject to the global phase III clinical research, and it is expected to be the first new drug of Sichuan to be marketed in the US.

 

● Chengdu Jinkai Biotech Co., Ltd. declared the clinical trial for SAL007 in the US.

 

● 41 biological projects have been introduced, with the total investment of RMB 16.6 billion.

 

● The Phase II Project of Chengdu Tianfu Bio-Industry Incubation Park[u1]  is also under preparation.

Where is the future potential and direction?

Pay attention to the transformation of excellent achievements.

 

Relevant responsible person of China National Center for Biotechnology Development said, “The biomedical industry needs to promote industrial development through technology. Chengdu has superior education resources and a large market. It should have a huge development space in bio-pharmaceuticals, medical equipment, and especially biomedical materials. If outstanding achievements can be transformed, there will be a number of products having certain impact on the world in the future to boost the development of the whole Park.”